Content Detail

• Content META

  Title	3 Penny Stocks to Watch for Big Gains in 2025
  ID	5264064
  External ID	7404649783
  Author	Aanchal Sugandh
  Published Date	Dec. 19, 2024, 12:52 p.m.
  Summary	The Federal Reserve's recent rate cut points to a steady but slowing economy. In this scenario, investing in penny stocks, Ribbon Communications Inc. ( Get Rating ), Ironwood Pharmaceuticals, Inc. ( G
  Tags	None
  URL	https://stocknews.com/news/rbbn-irwd-orgo-3-penny-stocks-to-watch-for-big-gains-in-2025/
  Sentiment	Negative: 0.04161    Neutral: 0.32650    Positive: 0.63190
  Relevance	0.02807

• Content Details

  Content ID	3182222
  Key	dd97aa12-925d-443c-8e5f-5b0f39e24f11
  Content	The Federal Reserve's recent rate cut points to a steady but slowing economy. In this scenario, investing in penny stocks, Ribbon Communications Inc. ( Get Rating ), Ironwood Pharmaceuticals, Inc. ( Get Rating ), and Organogenesis Holdings Inc. ( Get Rating ), all trading below $5, seems like a strategic move. Let us understand why. The Federal Reserve just delivered its third rate cut this year, lowering its key interest rate to a range of 4.25% to 4.5% . This quarter-point reduction is part of a strategy to maintain economic stability, even as the once-vigorous economy begins to cool off. In its latest statement, the Fed has revised its outlook, projecting only two interest rate cuts in 2025. While inflation remains somewhat elevated, the central bank does not anticipate achieving its 2% target until 2026. For now, unemployment rates remain low, signaling some resilience in the labor market. Despite inflation falling far below its pandemic-era peaks, the November Consumer Price Index showed a slight uptick, rising 2.7% year-on-year compared to October's 2.6%. This minor acceleration, though still manageable, underscores the persistence of price pressures in some sectors of the economy. Retail sales tell another story. November saw a 0.7% increase , beating forecasts of 0.6%, while October's figure was revised upward to 0.5%. These numbers highlight steady consumer confidence, even amid economic uncertainties, showcasing the surprising resilience of the American consumer. Yet, beneath this solid footing lies a mix of vulnerabilities. The Fed's more lenient monetary policy aligns with subtle warning signs of economic weaknesses. Even President-elect Donald Trump has advocated for such measures, recognizing the need for careful economic navigation. This environment could present a golden opportunity for investors to explore penny stocks. These low-priced, small-cap stocks are known for their volatility but also hold the potential for significant returns. Their affordability and capacity for high upside make them an intriguing choice for those seeking growth in uncertain times. So, let us dive deep into the fundamentals of three penny stocks, starting with #3. Stock #3: Ribbon Communications Inc. ( Get Rating RBBN is a communications technology company that operates through two segments: Cloud and Edge, as well as IP Optical Networks. It provides software and hardware products, solutions, and services for voice-over internet protocol communications, private, public, or hybrid cloud infrastructures, as well as data centers, enterprise premises, and more. On December 11, RBBN announced integrating its high-density Data Center Interconnect (DCI) solution into Diabolocom's AI-powered cloud contact center software. This partnership could boost RBBN's market presence in the communication technology sector and open its doors for future partnerships. On October 25, RBBN announced the completion of Dense Wave Division Multiplexing (DWDM) deployment for Airtel, one of India's top telecom providers. Global partnerships like this could strengthen RBBN's market dominance and deliver its high-quality connectivity solutions to enterprises worldwide. RBBN's trailing-12-month gross profit margin of 55.24% is 9.6% higher than the industry average of 50.41%. Its trailing-12-month asset turnover ratio of 0.72x is 17.6% higher than the industry average of 0.62x. Moreover, the company's trailing-12-month CAPEX/Sales margin of 2.12% is 3.7% higher than the industry average of 2.05%. For the fiscal third quarter that ended September 30, 2024, RBBN's total revenue increased 3.5% year-over-year to $210.24 million. Its adjusted EBITDA rose 8% from the year-ago value to $29.95 million. Additionally, the company's non-GAAP net income and non-GAAP EPS came in at $8.49 million and $0.05, respectively. Analysts expect RBBN's revenue and EPS for the fiscal fourth quarter ending December 2024 to increase 7.6% and 6.7% year-over-year to $243.61 million and $0.13, respectively. Shares of RBBN have surged 30.4% over the past six months and 47.7% over the past year, closing the last trading session at $3.90. RBBN's POWR Ratings mirror its solid fundamentals. It has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree. RBBN has a B grade for Growth and Momentum. Within the B-rated Technology – Communication/Networking industry, RBBN is ranked #12 out of 44 stocks. In addition to the POWR Ratings highlighted above, you can check RBBN's ratings for Stability, Sentiment, Value, and Quality here Stock #2: Ironwood Pharmaceuticals, Inc. ( Get Rating IRWD is a healthcare company focusing on the development and commercialization of gastrointestinal (GI) products. The company's pipeline includes drugs like linaclotide, IW-3300, Apraglutide, and CNP-104. On October 28, IRWD announced positive results from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, evaluating the treatment effect of apraglutide by baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure (SBS-IF). The analysis showed a consistent treatment effect across subgroups: gender, age, body weight, region, race, ethnicity and SBS characteristics. This advances the company's plans to gain FDA approval for apraglutide. IRWD's trailing-12-month gross profit margin of 66.86% is 14.6% higher than the industry average of 58.37%. Its trailing-12-month EBITDA margin of 25.74% is 327.6% higher than the 6.02% industry average. Additionally, the stock's trailing-12-month levered FCF margin of 21.06% is 887.5% higher than the sector average of 2.13%. For the fiscal third quarter that ended September 30, 2024, IRWD's total revenue came in at $91.59 million. Its adjusted EBITDA was reported to be $26.16 million. Moreover, its non-GAAP net income and non-GAAP net income per share amounted to $3.87 million and $0.02, respectively. For the fiscal year ending December 2025. Street expects IRWD's revenue to come in at $348.40. Meanwhile, its EPS for the same period is estimated to increase 38.6% year-over-year to $0.24. IRWD's shares declined 2% intraday to close the last trading session at $3.46. IRWD's robust prospects are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. IRWD has an A grade for Value and Quality. It is ranked #23 out of 152 stocks within the Medical – Pharmaceuticals industry. To access IRWD's Growth, Momentum, Sentiment, and Stability ratings, click here Stock #1: Organogenesis Holdings Inc. ( Get Rating ORGO is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets. Its products include Affinity, Novachor, Apligraf, Dermagraft, NuShield and more. On November 22, ORGO announced plans to expand its manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. This expansion could prove crucial to ORGO as it opens up paths for increased manufacturing and the company's overall growth. On November 11, ORGO announced a favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA) aimed at the management of symptoms associated with knee osteoarthritis (OA). With this positive outcome, ORGO is one step closer to a new clinical trial and eventually market ReNu, enhancing the company's osteopathic pipeline. ORGO's trailing-12-month gross profit margin of 75.29% is 29% higher than the industry average of 58.37%. Its trailing-12-month levered FCF margin of 2.96% is 38.9% higher than the sector average of 2.13%. Furthermore, the stock's trailing-12-month EBITDA margin of 6.32% is 4.9% higher than the 6.02% industry average. For the fiscal 2024 third quarter that ended September 30, ORGO's net revenue increased 6.1% year-over-year to $115.18 million. Its non-GAAP operating income came in at $7.08 million. Moreover, the company's adjusted EBITDA was reported to be $13.41 million. ORGO's adjusted net income and net income per share rose 144% and 350% from the year-ago value to $12.94 million and $0.09, respectively. The consensus revenue estimate of $472.94 million for the fiscal year ending December 2025 exhibits a year-over-year rise of 1.6%. Its EPS for the same period is expected to come in at $0.02. Moreover, the company topped the consensus revenue estimates in three of the four trailing quarters. The stock has surged 13.7% over the past three months and 31.2% over the past six months to close the last trading session at $3.24. ORGO's strong prospects are apparent in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system. ORGO has an A grade for Value and a B for Quality. Within the Biotech industry, it is ranked #8 out of 335 stocks. Click here to access ORGO's ratings for Growth, Stability, Sentiment, and Momentum. What To Do Next? Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets: RBBN shares were unchanged in premarket trading Thursday. Year-to-date, RBBN has gained 34.48%, versus a 24.51% rise in the benchmark S&P 500 index during the same period. About the Author: Aanchal Sugandh Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program. She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns. More... More Resources for the Stocks in this Article
  Content Reference URL	None

• Publisher

  Publisher Name	Stock News
  Publisher URL	https://stocknews.com
  Description	None
  Trust Flow Score	25
  Citation Flow Score	47

• Data Source

  Data Source Name	Quantexa News
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10